As Curis clinically backs a novel oncology mechanism, several companies might review their own similarly acting projects.
The SITC breaks its own embargo, and the ensuing chaos sees Replimune, Iovance and Incyte move.
The biotech calendar’s next key conference gets under way in a month, and a presentation by Nextcure will be a focus for some investors.
A cooling of the M&A climate allows Asia-based groups to come to the fore.